Trial Profile
Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood α-Synuclein
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Dementia; Lewy body disease; Parkinson's disease
- Focus Pharmacodynamics
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 27 Apr 2018 Results of alteration in CSF biomarkers presented at the 70th Annual Meeting of the American Academy of Neurology.
- 20 Jul 2017 Results of retrospective analysis presented at the Alzheimer's Association International Conference 2017